p32

p32 inhibitor M36 is an inhibitor of p32 mitochondrial protein. It binds directly to p32 and inhibits the p32 association with LyP-1.

P32/98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.

C5aR2 agonist P32 (Ac-RHYPYWR-OH) is a selective agonist for C5aR2. It has demonstrated the ability to trigger various immunomodulatory activities both in vitro and in vivo, as it can downregulate C5aR1-mediated cellular signaling and can also operate in a C5aR1-independent manner.

C5aR2 agonist P32 acetate (Ac-RHYPYWR-OH), a selective agonist for C5aR2, has been shown to induce various immunomodulatory activities both in vitro and in vivo. It modulates cell signaling via the downregulation of C5aR1-mediated pathways and can also function independently of C5aR1.

BIBP3226 TFA is an effective and selective antagonist of neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor (Kis: 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF).

BIBP3226 is a potent and selective antagonist for the Neuropeptide Y receptor (Y1) and the neuropeptide FF receptor (NPFF).

GP3269 is a selective, potent, orally active human adenosine kinase (AK) inhibitor (IC50: 11 nM) with anticonvulsant effects in rats.

Mouse IgG2A(L234A/L235A/P329G)-Kappa Isotype-control is the isotype control for Mouse IgG2A-Kappa antibody.

Human IgG4(S228P/L235E/P329G)-kappa Isotype control is the isotype control for Human IgG4(S228P/L235E/P329G)-kappa antibody.

Human IgG1(P329G/E356D/M358L)-kappa Isotype control is the isotype control for Human IgG1(P329G/E356D/M358L)-kappa antibody.

Human IgG1(L234A /L235A/P329G)-Kappa Isotype control is the isotype control for Human IgG1 (LALAPG)-Kappa antibody.

DP32 is a dual-function compound incorporating an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. It is applicable in analgesia-related research.

LyP-1 is a cyclic peptide comprised of 9 amino acids, designed to target and bind selectively to p32 receptors that are overexpressed in a range of tumor-associated cells.

LyP-1 acetate is a tumor homing peptide specifically binding to p32 receptors overexpressed in various tumor-associated cells.

D-erythro-Sphingosine (trans-4-Sphingenine) is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator

LyP-1 TFA, a cyclic nine-amino-acid peptide, exhibits selective binding to p32 receptors, which are overexpressed in a variety of tumor-associated cells [1].

The LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. It targets peritoneal cancer (PC) by binding to the p32 (gC1qR) receptor. The LinTT1 can associate with iron oxide nanohelical (NWs) structures to form a nanocarrier that is taken up by peritoneal cancer cells in vitro and penetrates mitochondria; it also shows significant tumor-targeting and penetration effects in vivo in mice. Furthermore, LinTT1-functionalized nanocarriers combined with the pro-apoptotic peptide [D(KLAKLAK)2] demonstrate substantial tumor inhibition in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery vehicle for peritoneal cancer research.